The Paradise uRDN system is currently commercially available for patients in the US having received FDA approval in November 2023. It is indicated to reduce blood pressure as an adjunctive treatment ...

Hypertension in pregnancy increases the likelihood of postpartum hypertension. Know the risk factors to start managing ...

The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

While high blood pressure can contribute to renovascular disease, having renal (kidney) problems can also increase blood ...

As prevalence of CVDs continues to increase, the AHA and AMA have developed the Target BP initiative to improve blood ...

Erri, S. and Oroszi, T. (2025) Isolated Systolic Hypertension in Geriatrics. International Journal of Clinical Medicine, 16, ...

Unfortunately, most New Year’s resolutions fail. A 2023 Forbes poll found that 44% of resolutions last just two to three ...

Time-restricted eating, particularly among people with underlying metabolic disorders, may confer benefits beyond weight loss ...

Targeted Medical Pharma, Inc. (OTCMKTS:TRGM – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and ...